Company Overview and News

55
Medical Device Firms in Focus on Expanded R&D Scope: 5 Picks

2018-06-26 zacks - 1
The U.S. Medical Device industry trend in 2018 is reflective of extensive discovery and innovation in the life sciences industry over the past few years.
STE VAR SYK IDXX CERN ISRG ABMD ROSA

166
MedTech Overcomes Policy Hurdles, Long-Term Prospects Bright

2018-06-16 zacks - 1
With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism. AdvaMed, the medical device industry’s lobbying group, which strongly advocated for this relief, noted that the tax repeal will provide a huge impetus to the companies to channelize their turnovers into strategic consolidations, research and developments and also help in creating new job opportunities.
IFK TGTX NXTM SRXTY BAX OSUR 1302 BSX SYK INSY CAH SRX SXMDF IFX ISRG HSIC 0165 MDT EGRX FTV JNJ SRDX ABMD ROSA

78
The Zacks Analyst Blog Highlights: Cerner, AmerisourceBergen, Fresenius and Olympus

2018-03-21 zacks
Chicago, IL – March 21, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Cerner Corporation (CERN - Free Report) , AmerisourceBergen Corporation (ABC - Free Report) , Fresenius Medical Care (FMS - Free Report) and Olympus Corp.
OCPNY NXTM ABCO CVS ABC CERN MS ROSA

48
Goldman Sachs Backs Emerging Markets: MedTech Stocks in Focus

2018-03-20 zacks
Emerging market investment has taken a backseat of late, thanks to the nonstop blows to the economy. The lingering geopolitical tension in Gulf, debt and policy related hazards in Latin America or the missile tests in North Korea have led stock investors to reconsider their outlay in these markets, earlier proclaimed to offer better growth opportunities than the United States. Going by the MSCI Emerging Markets Index, the last five-year annualized growth rate was just 5.
IFK IFX BSX JNJ MCFT ROSA MDT

67
3 Favorable Trends Dispelling Tax-Repeal Worries in MedTech

2018-03-20 zacks
The tax-repeal saga has been dominating the headlines of the U.S. MedTech industry since the last couple of months.
ABC OCPNY CERN NXTM ABCO MCFT ROSA CVS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to EPA:ROSA / MEDTECH on message board site Silicon Investor.

Petition to Ban *ROSARIO* from SI Petition to Ban *ROSARIO* from SI Petition to Ban *ROSARIO* from SI The *ROSARIO* Hall of fame. The *ROSARIO* Hall of fame. The *ROSARIO* Hall of fame.